This is the authors' abstract. We don't add key points for this paper.
Most children with B-lymphoblastic leukemia (B-ALL) are cured by modern chemotherapy immunotherapy, but their burden of treatment-related toxicity underscores a need to further refine risk-adapted therapy.Prognostic advances from frontline incorporation of blinatumomab 1 have stimulated interest in testing whether carefully selected, favorable-risk groups might safely benefit from chemotherapy deescalation.The responsible design of such studies requires a clear understanding of how all prognostic information should inform eligibility.Minimal/measurable residual disease (MRD) at the end of induction (EOI) remains one of the strongest predictive tools for guiding postinduction treatment intensity for pediatric B-ALL. 2 High-throughput sequencing (HTS) of clonal immunoglobulin gene rearrangements enhances MRD detection sensitivity below the typical 0.01% threshold of flow cytometry MRD (fcMRD) and provides clinically actionable prognostic information, with the guiding principle that patients who achieve and sustain undetectable HTS-MRD fare better than those with MRD persistence.[3][4][5][6] However, because MRD behaves as a continuous variable with unique, subgroup-specific thresholds, 7,8 the clinical relevance of low-level detection in the context of a specific treatment regimen may not be uniform across all patients.In particular, children classified as Standard Risk-Favorable (SR-FAV) by criteria defined in the Children's Oncology Group (COG) trial AALL1731 1 have consistently outstanding outcomes with chemotherapy alone, 9,10 but the AALL1731 stratification schema, now widely adopted in most of North America, did not incorporate HTS-MRD evaluation for SR-FAV assignment.HTS-MRD has clear prognostic value and is frequently evaluated before final risk group assignment.Thus, defining how EOI HTS-MRD should influence SR-FAV eligibility remains an unresolved gap in current practice.In the largest published pediatric HTS-MRD analysis to date, Wood et al. 3 retrospectively evaluated EOI HTS-MRD using bone marrow samples from a subset of patients from COG AALL0331 11 and AALL0232.12 Of the 296 evaluable National Cancer Institute Standard Risk (age, ≥1 to <10 years; white blood cell count, <50 × 10 3 /μL) patients, 3,13 53 met AALL1731-defined SR-FAV criteria by retrospective classification (Figure 1A).Day 8 peripheral blood (PB) fcMRD was unavailable for 19 patients; therefore, this parameter was omitted from classification.Four patients lacked trackable sequence(s) at diagnosis.Thus, we analyzed the incidence and prognostic relevance of EOI HTS-MRD in 49 SR-FAV patients (supplemental Table 1).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fries et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: